Perseus-Soros Management has sold its remaining 1.7 million share stake in drug company Adams Respiratory Therapeutics (Nasdaq: ARXT) for around $44 million, according to The New York Post.
Perseus-Soros Management has sold its remaining 1.7 million share stake in drug company Adams Respiratory Therapeutics (Nasdaq: ARXT) for around $44 million, according to The New York Post.
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.